Yes Sam, Rexista can be commercialized with PODRAS as part of the deal. As PODRAS tech becomes mature, Rexista II will then replace Rexista even if Rexista was already out on the market. They can simply apply for label on the new version. It makes sense that a buyer would want a deal in this fashion.
The way I understand it is that both nPODDDS and PODRAS are derived from the same hypermatrix delivery tech they started out investigating. It leads me to believe the PODRAS is basically a modification of nPODDDS. So, it shouldn't be hard to apply that to make Rexista II once the concept is proven in tests that it works reliably and effectively.
As to the stock price, sit back and it will rise over time. I bought back in a lot more this time around and it's doing great since my entry at 1.92.
News 
Market Data 
Discover 
AI
